Scituzumab Thyrumotecan vs Platinum Chemotherapy in EGFR-Mutated NSCLC: OptiTROP-Lung04 Trial
TribeMD
3 min read
October 19, 2025
Carregando conteúdo…
ESMO®2025
Oncology
Highlights
TribeMD
ASCO GU® 2026
TribeMD
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
TribeMD
SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care
TribeMD
ASCO GU® 2026
TribeMD
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
TribeMD
SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care